排序方式: 共有104条查询结果,搜索用时 15 毫秒
1.
Doundoulakis Ioannis Gavriilaki Maria Tsiachris Dimitris Arsenos Petros Antoniou Christos-Konstantinos Dimou Smaro Soulaidopoulos Stergios Farmakis Ioannis Akrivos Evangelos Stoiloudis Panagiotis Notas Konstantinos Kimiskidis Vasilios K. Giannakoulas George Paraskevaidis Stylianos Gatzoulis Konstantinos A. Tsioufis Konstantinos 《Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy》2022,36(5):951-958
Cardiovascular Drugs and Therapy - Atrial high-rate episodes (AHREs) recorded with cardiac implantable electronic devices (CIEDs) have been associated with the development of clinical atrial... 相似文献
2.
Ticlopidine-induced aplastic anemia: two new case reports,review, and meta-analysis of 55 additional cases 总被引:2,自引:0,他引:2
Symeonidis A Kouraklis-Symeonidis A Seimeni U Galani A Giannakoulas N Fragopanagou E Tiniakou M Matsouka P Zoumbos N 《American journal of hematology》2002,71(1):24-32
Ticlopidine-induced aplastic anemia (TIAA) is considered very uncommon. We present two new cases, and we review 55 additional cases from the literature. The first case concerns a 70-year-old man who developed severe aplastic anemia 7 weeks after treatment with 500 mg of ticlopidine daily. The patient sustained a severe septic episode, was treated with antibiotics and GM-CSF, and recovered the 14(th) day after ticlopidine withdrawal. The second was an 82-year-old man receiving ticlopidine for 2 years when, during a febrile episode, he was found neutropenic with marrow aplasia. Ticlopidine withdrawal and treatment with antibiotics, transfusions, and G-CSF helped him to recover. When the data of the 57 patients are evaluated, a reversible direct cytotoxic effect of ticlopidine on the pluripotent/bipotent hematopoietic progenitor stem cell is proposed. It is estimated that the real incidence if TIAA is higher, and many cases, initially presented as agranulocytosis +/- thrombocytopenia, might be true aplastic anemias, not proven by marrow aspiration or trephine biopsy. There is no effective monitoring to prevent this side effect. Recombinant growth factors appear not to help in shortening the neutropenic period. 相似文献
3.
D Siagris N Giannakoulas M Christofidou A Tsamandas A Lekkou K Thomopoulos N Zoumbos Ch Labropoulou-Karatza 《Liver international》2004,24(3):204-209
OBJECTIVES: Multitransfused adult beta-thalassemic patients constitute a population with high prevalence of hepatitis C virus (HCV) infection, because of transmission of HCV from infected blood donors prior to the introduction of anti-HCV screening. The aim of this study was to compare them with otherwise normal patients with HCV infection. METHODS: Forty-two adult multitransfused beta-thalassemics and 49 otherwise normal patients of the same age, with chronic HCV infection were studied. Viral parameters, autoimmunity indices and liver histology were evaluated. RESULTS: Serum HCV RNA levels were found significantly lower in thalassemic (median: 65,150 international units per milliliter (IU/ml); range: 3 059 380 IU/ml) than in non-thalassemic (NT) patients (median: 580,000 IU/ml; range: 10,956,000 IU/ml; P=0.001). The most prevalent genotype in thalassemic group was genotype 4 (32.4%) while in NT group was genotype 3a (59.2%). Cryoglobulins were detected in 8/42 (19%) thalassemic patients and in 12/49 (24.5%) NTs. Thalassemic patients had significantly lower levels of C3 and C4 components of complement and higher incidence of anti-nuclear antibodies than those without thalassemia. In patients with thalassemia a lower grading score was noted in liver biopsy compared with those without thalassemia (4.41+/-1.98 vs 5.38 +/- 2.09, P=0.038). On the contrary, thalassemic patients were found to have a higher staging score (3.08 +/- 1.51 vs 2.33 +/- 1.34, P=0.024). CONCLUSIONS: Adult beta-thalassemic patients, compared with other patients with HCV infection, present lower necroinflammatory activity and lower viral load but higher staging score. Autoimmune features are marginally different. Age of acquiring the infection, iron overload and modulation of immune system by transfusions are the proposed causes of these differences. 相似文献
4.
5.
6.
7.
Farmakis Dimitrios Chrysohoou Christina Giamouzis Gregory Giannakoulas George Hamilos Michalis Naka Katerina Tzeis Stylianos Xydonas Sotirios Karavidas Apostolos Parissis John 《Heart failure reviews》2021,26(6):1345-1358
Heart Failure Reviews - Heart failure (HF) and atrial fibrillation (AF) often coexist, being closely interrelated as the one increases the prevalence and incidence and worsens the prognosis of the... 相似文献
8.
V. Kamperidis S. Hadjimiltiades S.A. Mouratoglou A. Ziakas G. Sianos A. Sarafidou I. Ventoulis G. Kazinakis G. Giannakoulas G.K. Efthimiadis G. Parcharidis H. Karvounis 《Herz》2016,41(2):144-150
Background
Balloon aortic valvuloplasty (BAV) has been revived as a bridge to transcatheter aortic valve replacement (TAVR). The aim of the current prospective study was to define a safe time period from BAV to TAVR and to determine hemodynamic variables that predict event-free survival after BAV.Patients and methods
The present prospective study included 68 consecutive patients with severe aortic stenosis who were treated initially with BAV from 2009 to 2012. Echocardiographic and invasive hemodynamic assessments were performed before BAV. The patients were followed up at regular intervals and events were defined as cardiac hospitalization or death.Results
Invasive hemodynamic evaluation yielded more favorable results than echocardiographic assessment: aortic stenosis was less severe, cardiac output was higher, and pulmonary capillary wedge pressure (PCWP) was lower. Post-BAV event-free survival was 80.4?% at 30 days, 64.5?% at 6 months, 37?% at 1 year, 22.3?% at 2 years, and 9.3?% at 3 years. After excluding pre-discharge deaths (n?=?7), the 30-day event-free survival rate was 90?%. Predictors of events after BAV were atrial fibrillation, cardiogenic shock, elevated euroSCORE (European System for Cardiac Operative Risk Evaluation), elevated PCWP, and elevated pulmonary artery systolic pressure. Invasively measured PCWP was the only independent predictor of events (hazard ratio, 1.07; 95?% confidence interval, 1.03–1.11; p?=?0.001).Conclusion
A 30-day post-BAV period may be considered a bridge to TAVR. Furthermore, invasive assessment of PCWP before BAV is an independent hemodynamic predictor of events after BAV.9.
Filippos K. Triposkiadis Javed Butler Georgios Karayannis Randall C. Starling Gerasimos Filippatos Kathy Wolski John Parissis Charalabos Parisis Dimitrios Rovithis Konstantinos Koutrakis John Skoularigis Christos-Konstantinos Antoniou Christina Chrysohoou Christos Pitsavos Christodoulos Stefanadis John Nastas Themistoklis Tsaknakis Lilian Mantziari Georgios Giannakoulas Haralambos Karvounis Andreas P. Kalogeropoulos Gregory Giamouzis 《International journal of cardiology》2014
Aims
The role of low-dose dopamine infusion in patients with acute decompensated heart failure (ADHF) remains controversial. We aim to evaluate the efficacy and safety of high- versus low-dose furosemide with or without low-dose dopamine infusion in this patient population.Methods and results
161 ADHF patients (78 years; 46% female; ejection fraction 31%) were randomized to 8-hour continuous infusions of: a) high-dose furosemide (HDF, n = 50, 20 mg/h), b) low-dose furosemide and low-dose dopamine (LDFD, n = 56, 5 mg/h and 5 μg kg− 1 min− 1 respectively), or c) low-dose furosemide (LDF, n = 55, furosemide 5 mg/h). The main outcomes were 60-day and one-year all-cause mortality (ACM) and hospitalization for HF (HHF). Dyspnea relief (Borg index), worsening renal function (WRF, rise in serum creatinine (sCr) ≥ 0.3 mg/dL), and length of stay (LOS) were also assessed. The urinary output at 2, 4, 6, 8, and 24 h was not significantly different in the three groups. Neither the ACM at day 60 (4.0%, 7.1%, and 7.2%; P = 0.74) or at one year (38.1%, 33.9% and 32.7%, P = 0.84) nor the HHF at day 60 (22.0%, 21.4%, and 14.5%, P = 0.55) or one year (60.0%, 50.0%, and 47%, P = 0.40) differed between HDF, LDFD, and LDF groups, respectively. No differences in the Borg index or LOS were noted. WRF was higher in the HDF than in LDFD and LDF groups at day 1 (24% vs. 11% vs. 7%, P < 0.0001) but not at sCr peak (44% vs. 38% vs. 29%, P = 0.27). No significant differences in adverse events were noted.Conclusions
In ADHF patients, there were no significant differences in the in-hospital and post-discharge outcomes between high- vs. low-dose furosemide infusion; the addition of low-dose dopamine infusion was not associated with any beneficial effects. 相似文献10.
George Giannakoulas Sophia-Anastasia Mouratoglou Michael A. Gatzoulis Haralambos Karvounis 《International journal of cardiology》2014